secwatch.observer — SEC 8-K summary
======================================

Issuer:     SYNLOGIC, INC. (SYBX)
CIK:        0001527599
Form:       8-K
Filed at:   2023-03-29T23:59:59+00:00
Accession:  0000950170-23-010430
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Synlogic reports Q4 2022 net loss $16.7M; PKU Phase 3 on track for H1 2023
--------------------------------------------------------------------------

- Q4 2022 net loss $16.7M ($0.24/share) vs $15.1M ($0.21) in Q4 2021; full year net loss $66.1M ($0.92/share).
- Cash, cash equivalents and marketable securities $77.6M; projected runway into H2 2024.
- PKU program SYNB1934 on track for Phase 3 trial initiation in H1 2023; Rare Pediatric Disease Designation granted.
- SYNB1353 for HCU received Rare Pediatric Disease Designation; proof of mechanism in Phase 1 study.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1527599/000095017023010430/0000950170-23-010430-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1527599/000095017023010430/sybx-20230329.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-010430

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer